Paradigm Biopharmaceuticals Ltd (ASX:PAR) director Christopher Fullerton has purchased 100,000 shares on-market for a total consideration of $118,116.
The transaction brings Fullerton’s total holding (direct and indirect) to 836,000 shares.
READ: Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial
The company has begun discussions with International key opinion leaders (KOL’s) for mucopolysaccharidoses (MPS) clinical trial design and site selection.
MPS is a progressive rare disease caused by the absence or malfunctioning of lysosomal enzymes and has a severe unmet need.
Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS), a US FDA approved drug that has a long track record of safely treating inflammation.
The company is confident that a single successful phase 2/3 clinical trial will enable iPPS to be registered as a treatment for certain MPS indications.